Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer Sees Xarelto Being Profitable In 2014 As New Drugs Deliver

This article was originally published in The Pink Sheet Daily

Executive Summary

Bayer’s pharma sales surged in the second quarter, driven by heart drug Xarelto, new ophthalmic Eylea and cancer treatment Stivarga, prompting the German blue chip to raise its sales forecast for medicines this year and assert that its new oral anticoagulant probably will become profitable in 2014.


Related Content

Bayer Taps Pfizer Emerging Markets Head To Lead Health Care Division
Daiichi Sankyo’s Edoxaban Could Find Role In Treating Sickest Patients
Bayer Launches Stivarga In Malaysia And Singapore For Terminal Colorectal Cancer Patients To Prolong Survival
As Eliquis Sales Lag, Bristol/Pfizer Take Action
Bayer’s Reinhardt Returning To Novartis To Replace Departing Vasella


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts